Forgot your password?

Approvals/Requirements Satisfied by eRADIMAGING Courses
~ ASRT approval for ARRT® Category A credit   ~ MDCB approval by the Medical Dosimetrist Certification (Selected Courses)
~ ARMRIT accepted (All MRI Courses) ~ CAMRT and Sonography Canada recognize the ASRT approval (All Courses)
~ ARDMS accepted (All Courses) ~ Florida approval for all courses 1 credit or more
~ NMTCB accepted (All Courses) ~ California CE requirements met for all radiography courses
~ All Courses eligible of international radiographers' CPD requirements ~ All Courses available for RRAs
~ ASRT and MDCB are approved continuing education providers of ARRT® and all courses are accepted by ARRT®

The Role of Radiolabeled PET/CT in the Diagnosis and Characterization of Prostate Cancer

Steven Marks*

*President, MedCom Consultants, Inc, Potomac MD

Address correspondence to: Steven Marks, MedCom Consultants Inc, 1311 Fallsmead Way, Potomac MD 20854. Email: steven.marks52@gmail.com

Disclosure statement: Steven Marks reports having no financial or advisory relationship with any corporate, medical, or political organization doing work related to this paper or other business activity at MedCom Consultants, Inc.



Prostate cancer (PCa) is the most commonly diagnosed noncutaneous malignancy among Americans, with an incidence of more than 160,000 and a prevalence approaching 3 million. Each year about 30,000 American males die because of PCa, while worldwide mortality now approaches 260,000 annually. The natural history of PCa is heterogeneous, as the majority of lesions remain intraprostatic and indolent. However, nearly 30% of all tumors are rapidly progressive, metastatic, and highly resistant to treatment. As the vast majority of tumors are not clinically meaningful, the usefulness of screening and early detection is controversial. The standard diagnostic and staging methodology, transrectal ultrasonography-guided systemic biopsy, does not provide a meaningful biologic characterization of PCa, particularly when the disease has metastasized. Although functional magnetic resonance imaging is the most efficacious modality for evaluating primary PCa, its accuracy in staging regional and metastatic disease is low. Radiolabeled positron emission tomography/computed tomography (PET/CT) imaging, by contrast, offers a more reliable description of the molecular characteristics of the disease, as well as a clearer depiction of biochemical recurrence and metastases to the lymph nodes and bone. This review will explore the role of functional PET/CT and the performance of the most important tracers now in clinical and research use for the detection and characterization of primary disease, PCa recurrence following radical prostatectomy or radiation therapy, and metastases to the lymph nodes and bone.

Full Course Content available to active members of eRADIMAGING.com

Sample eRADIMAGING Course *

* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.

Follow us on social media